Note: Italicized _f_ and _t_ refer to figures and tables.

ABCA1 transport protein, 33  
ACCORD, 199  
acute insulin response (AIR), 2, 3–5_f_  
acylation stimulating protein (ASP),  
101_f_  
adipocytes, 100, 121  
adiposity, 108  
Adult Treatment Panel, 158, 163_t_,  
181  
ADVANCE, 205–6  
adverse life events, 47–8  
aerobic exercise training, 88, 89_t_  
age, 163_t_  
Air Force/Texas Coronary Atherosclerosis  
Prevention Study, 158  
albuminuria, 208  
alcohol consumption, 35, 221–2  
alpha-linolenic acid (ALA), 64_t_, 65  
Alzheimer disease, 100–101  
American Cancer Society Prevention  
Study, 183  
amino acid metabolism, and insulin  
regulation, 12  
angina pectoris, 137  
angiotensin converting enzyme (ACE),  
101_f_  
angiotensin receptor blockers (ARB), 142,  
143_t_  
anangiotensin-converting enzyme inhibitors  
(ACEI), 142, 143_t_  
animal protein, 68  
antioxidant, 70  
antipsychotic drugs, 47  
antiretroviral therapy, 162  
apnea-hypopnea index, 186  
apolipoprotein B lipoproteins  
clinical applications, 23  
measuring, 31–2  
structure, 19_f_  
synthesis and secretion, 22  
apolipoprotein C-II, 23–4  
apolipoprotein C-III, 24–5, 24_f_, 34–5  
apolipoprotein E, 24–5, 24_f_  
apolipoprotein E4, 101  
arachidonic acid, 64_f_  
arrhythmias, 104–5  
arterial stiffness, 86–7  
atherogenic dyslipidemia, 35–6, 84–5  
atherosclerosis, 41–4  
decreased oxygen supply, 44–5  
endothelial injury or dysfunction, 42  
fibrinolysis, 42  
increased blood rheology, 44–5  
inflammation, 44  
lipids and lipid metabolism, 44  
obesity and, 101–4
atherosclerosis (Cont.)
  pathophysiology, 102–3
  revascularization procedure, 103–4
  thrombosis, 42
atorvastatin, 165f, 166
atrial fibrillation, 104–5, 140–41, 149f

bariatric surgery, 127, 191
Beck Depression Inventory score, 47
Behavioral Risk Factor Surveillance System (BRFSS), 226

beta-blockers, 162
beta-cell function
  changes in, 7f
  insulin sensitivity and, 2–8
  oral testing, 8–9
bile acid resins, 169–70
  effects on serum lipids, 164f
  mechanisms of action, 169
  side effects, 169–70
blood flow, and smoking, 44–5
blood pressure, 142
  ACCORD study, 203
  controlling, 222
  diabetes mellitus and, 142
  diastolic, 83
  goals in diabetic patients, 143f
  resistance exercise for, 83
  systolic, 83
body mass index (BMI), 96–7, 97f, 98–100, 106–7, 147f
body weight, 60
bodyweight regulation, 13–14
brachial artery flow-mediated dilation (BAFMD), 85
bupropion, 48, 50–51

calcium channel blockers, 162
campesterol, 69
canola oil, 65
carbohydrate receptor element binding protein (ChREBP), 11
carbohydrates, 67–8. See also nutrition
  fiber, 67
  fructose, 68
cardiac failure, 139–40
cardiomyopathy, 104, 139–40
cardiorespiratory fitness, 87
Cardiovascular Health Study, 107

cardiovascular morbidity
  in diabetes mellitus, 136–9
  exercise and, 79–80
  weight loss and, 184–92
  diabetes, 187–92
  dyslipidemia, 186–7
  heart disease, 184–6
  hypertension, 184–6
  obstructive sleep apnea, 186

cardiovascular mortality
  exercise and, 79–80
  smoking and, 41
  weight loss and, 183–4

cardiovascular risk
  diabetes mellitus and, 134–49
  lipoprotein metabolism and, 18–36
  metabolic factors, 82–90
  metabolic syndrome and, 119–27
  nutrition and, 59–70
  obesity and, 96–111
  physical activity and, 77–90
  tobacco use and, 41–53

cardiovascular risk reduction
  diabetes management and, 198–214
  lifestyle and, 220–29
  lipid management and, 164–74
  multifactor interventions, 222–3
  obesity management and, 181–91
  carotid intimal-medial thickening, 85–6

Centers for Disease Control, 136
  central obesity, 98, 99f
  ceramides, 11
  cholesterol, dietary, 67
  cholesterol absorption inhibitors, 164f
  Cholesterol and Recurrent Events (CARE), 158
  cholesterol ester transfer protein (CETP), 33–4
  Cholesterol Treatment Trialists’ Collaborators, 158
  cholesteryl ester transfer protein (CETP), 101f
  cholestyramine, 169–70
chylomicrons, 20–22
  in intestinal lipoprotein metabolism, 20
  structure, 19

clonidine, 48

cigarette smoking, 223–4
  adverse life events and, 47–8
  age, 52
  atherosclerosis and, 41–4
    decreased oxygen supply, 44–5
    endothelial injury or dysfunction, 42
    fibrinolysis, 42
    increased blood rheology, 44–5
    inflammation, 44
    lipids and lipid metabolism, 44
    thrombosis, 42
  cardiovascular deaths, 41
  cardiovascular dysfunction, 43
  cardiovascular function and, 44
  cessation
drugs, 48–50
  effectiveness of, 48–52
  inpatient programs, 51–2
  weight gain and, 46
demographics, 52
etnicity, 52
gender, 52
genetic factors, 48
  giving up, 221
  ischemic heart disease and, 41–2
  metabolic syndrome and, 45–8
    adverse life events, 47–8
    depression, 46–7
    genetic factors, 48
    risk factors, 46
  and risk for coronary heart disease, 163
  tobacco use, 52
  withdrawal symptoms, 47
  women smokers, 46

clinical trials, 200–211
  ACCORD, 200–204
  ADVANCE, 205–6
  meta-analyses, 211–14
  PROactive, 210–11
  UKPDS, 208–10
  VADT, 206–8
clofibrate, 174
corn syrup, 68
coronary artery disease, 101–4
  obesity and, 101–4
  pathophysiology, 102–3
  revascularization procedure, 103–4
coronary heart disease (CHD)
  cholesterol theory, 32
  exercise and, 80–81, 224–6
  ischemic, 137
  LDL-C as predictor of, 32
  residual risk, 35–6
  risk factors, 163
  C-reactive protein, 147

DASH diet, 184
dementia, 99t
depression, 46–7
Diabetes Complications and Control Trial (DCCT), 141
Diabetes Control and Complications, 199
diabetes mellitus, 134–49
  biological markers, 147
  cardiovascular morbidity, 136–9
    angina pectoris, 137
    myocardial infarction, 137–9
  clinical trials, 200–10
    ACCORD, 200–204
    ADVANCE, 205–6
    PROactive, 210–11
    UKPDS, 208–10
    VADT, 206–8
  controlling, 222
coronary artery calcification, 140
diabetes mellitus, (Cont.)
  deaths from, 135–6
  diagnostic criteria, 134
  frequency, 134
  prevalence, 134–5
  risk factor control, 147–9
  risk factors, 141–7
    blood pressure, 142
    glycemic control, 141–2
    kidney disease, 142
    lipids, 142–6
    microalbuminuria, 142
    obesity, 146–7
  risk of vascular events, 147–9
  subclinical cardiovascular diseases and,
    139–41
    atrial fibrillation, 140–41
    autonomic abnormalities, 140–41
    cardiac failure, 139–40
    cardiomyopathy, 139–40
    conduction disorders, 140–41
    heart rate variability, 140–41
  type 1
    insulin and, 2
    mortality rate, 135
  type 2
    high-fructose diet and, 68
    insulin deficiency in, 2, 9
    insulin resistance in, 2
    lifetime risk, 135
    mortality rate, 135
    weight loss and, 187–92
    bariatric surgery, 191
    medications, 187–91
    metabolic syndrome, 191–2
    sibutramine, 189–91
Diabetes Prevention Program, 187, 188f
diacetylglycerol, 11
diacetylglycerol acyltransferase, 172
diastolic blood pressure, 83
diet, 221, 227–8
  dietary carbohydrate, 67–8
    fiber, 67
    fructose, 68
  dietary cholesterol, 67, 162
  dietary fat, 59–61. See also nutrition
  body weight and, 60
  lipoprotein profiles, 60–61
  Mediterranean diet, 60
  polyunsaturated fatty acids, 63–6
  saturated fatty acids, 63–4
  types of, 61–7
  dietary fatty acids, 63–7
    common names/formulas, 64f
    dietary, 64f
    omega-3 polyunsaturated fatty acids, 65–6
    polyunsaturated fatty acids, 63–6
    saturated fatty acids, 63
    trans fatty acids, 66–7
  dietary fiber, 67
  dietary supplements, 69–70. See also
    nutrition
    antioxidants, 70
    phytosterols, 69
    policosanols, 70
docosahexaenoic acid (DHA), 64f, 65–6,
    174
dyslipidemia, 35–6
  atherogenic, 35–6, 84–5
  at-risk patient, 161–2
  diagnosis, 160–61
  in metabolic syndrome, 99f
  pharmacological management, 164–74
    bile acid resins, 169–70
    cholesterol absorption inhibitors, 170–71
    fibrin acid derivatives, 173–4
    nicotinic acid, 171–2
    omega-3 fatty acids, 174
    statins, 165–9
  risk factors, 36f
    weight loss and, 186–7
ectopic fat, 12–13
eicosapentaenoic acid (EPA), 64f,
  65–6, 174
elaidic acid, 64f
electrocardiogram (ECG), 104–5, 105f
endothelial dysfunction, 42
energy balance, 182f
energy expenditure (EE), 78
Index
high-density lipoprotein (Cont.)
vascular events in diabetic patients, 149
high-density lipoprotein (HDL), 32–5, 160–61
clinical applications, 35
function and dysfunction, 34–5
metabolism, 33 f
proinflammatory, 34
reverse cholesterol transport, 33 f
HM74A receptor, 171
homeostasis model (HOMA), 9 f
hydrogen peroxide, 43 f
hydrogenated fat, 66
hyperaminoacidemia, 12
hypercholesterolemia, 29–30
familial, 29–30
large low-density lipoprotein in, 32
MTP inhibitors, 23
policosanols and, 70
hyperglycemia, 2, 6, 121, 126, 199
hyperinsulinemia, 13
hypertension, 82–3, 99 t, 163 f, 184–6
hypertriglyceridemia, 11, 23, 25–7, 26 f, 61
hypobetalipoproteinemia, 28
hypoglycemia, 1–2, 202
hypothalamus, 1
hypothyroidism, 161
impaired fasting glucose (IFG), 2, 4 f, 6, 8–9
impaired glucose tolerance (IGT), 6, 7 f, 8–9, 10 f
indapamide, 205–6
Indian Diabetes Prevention Program, 187
Indian Diabetes Prevention Program (InDPP), 187
inflammatory markers, 147
insulin, 1
beta-cell function and, 2–8
functions of, 1
regulation of amino acid metabolism, 12
sensitivity, 2–8
insulin deficiency
bodyweight regulation and, 13–14
free fatty acids and, 11–12
lipid metabolism and, 11–12
regulation of fuel partitioning and, 9–11
insulin resistance. See also diabetes mellitus
bodyweight regulation and, 13–14
ectopic fat and, 12–13
epidemiology, 120–21
etiology, 121
fat distribution and, 12–13
free fatty acids and, 11–12
lipid metabolism and, 11–12
metabolic syndrome and, 119–20
pathophysiology, 121–3, 122 f
regulation of fuel partitioning and, 9–11
Insulin Resistance Atherosclerosis Study, 139
insulin sensitivity, 2–8
oral testing, 8–9
insulin sensitivity index (S_i), 2, 3–5 f, 6
insulin-receptor substrate-1 (IRS-1), 11
insulin-receptor substrate-2 (IRS-2), 11
interleukin, 101 f
intermediate-density lipoprotein (IDL), 166
intestinal triglyceride-rich lipoproteins, 20–22, 20 f
intra-abdominal fat (IAF), 12–13
intramyocellular lipid (IMCL), 13
IP-TFA (industrially-produced trans fatty acids), 228–9
ischemic heart disease, 41–2
and smoking, 41–2
isoflavones, 68–9
Japanese Diabetes Prevention Program, 187
Japanese Diabetes Prevention Program (JaDPP), 187
Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 51
JUPITER study, 158–9
ketosis, 2
laropiprant, 172
lauric acid, 63, 64
leisure-time physical activity (LTPA), 81
leukocyte, 147
Lifestyle Heart Trial, 185
lifestyle modifications, 162, 220–29
alcohol consumption, 221–2
blood pressure, 222
diabetes control, 222
diet, 221, 227–9
medications, 222
physical activity, 221, 224–6
sleep, 227–8
smoking, 221, 223–4
weight control, 221
linoleic acid, 64
linolenic acid, 64
lipemia retinalis, 161
lipid management, 156–75
clinical trials, 156–9
diagnosis of dyslipidemia, 160–61
evidence, 156–9
guidelines, 162
identification of at-risk patient, 161–2
lifestyle modifications, 162
pharmacological management, 164–74
bile acid resins, 169–70
cholesterol absorption inhibitors, 170–71
fibric acid derivatives, 173–4
nicotinic acid, 171–2
omega-3 fatty acids, 174
statins, 165–9
lipid metabolism
insulin deficiency and, 11–12
insulin resistance and, 11–12
smoking and, 44
Lipid Research Clinics Coronary Primary Prevention Trial, 156
lipogenesis, 1
lipoprotein lipase, 23–4, 101
lipoprotein(a), 30, 161
lipoproteins, 18–19
chylomicrons, 20–22
fasting vs. postprandial measurements, 21–2
profiles, 60–61
triglyceride-rich, 20–22
very-low-density lipoproteins, 22–7
lipotoxic state, 121
Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID), 158
Look AHEAD trial, 188
lovastatin, 165
low-density lipoprotein cholesterol (LDL-C), 30–31
coronary heart disease and, 35
diabetes and, 143–4, 144–6
dietary carbohydrate and, 68
dietary fat types and, 62, 62
goals and risk categories, 164
phytosterols and, 69
risk category and treatment goals, 146
as risk factor for CVD, 61
risk for nonfatal MI and CHD death, 159
risk of CHD death, 145
size and density, 32
smoking and, 44
statin therapy, 157–9, 166
value and classification, 163
low-density lipoprotein (LDL), 19, 27–32
circulation time, 28
clinical applications, 29–30
concentration, regulators of, 28–9, 29
diagnosis of dyslipidemia, 160
lipoprotein(a), 30
size and density, 32
statin therapy, 166
structure, 19
low-fat diet, 60
macroalbuminuria, 208
margarines, 227–8
Mediterranean diet, 60, 162
mental health, 46–7
metabolic memory, 142
metabolic syndrome, 119–20, 181–2
cardiovascular risk, 123–4
definitions of, 99, 119–20
diabetes and, 191–2
diagnosis and evaluation, 124–5
diagnostic testing, 125
history, 124–5
physical examination, 124–5
diagnostic criteria for, 120f
dyslipidemia and, 36f
epidemiology, 120–21
hypertriglyceridemia in, 11
incidence of, 120
pathophysiology, 121–3, 122f
prevalence of, 120–21
smoking and, 45–8
adverse life events, 47–8
depression, 46–7
genetic factors, 48
risk factors, 46
trans fatty acids and, 228–9
treatment, 125–7
non-pharmacological, 125–6
pharmacological, 126–7
surgical, 126–7
metformin, 10f, 126
microalbuminuria, 142, 208
microsomal triglyceride transfer protein (MTP), 23
mitochondrial electron transport chain (METC), 43f
monocyte-chemoattractant protein (MCP), 101f
monounsaturated fats, 162
morbidty, cardiovascular
in diabetes mellitus, 136–9
exercise and, 79–80
weight loss and, 184–92
diabetes, 187–92
dyslipidemia, 186–7
heart disease, 184–6
hypertension, 184–6
obstructive sleep apnea, 186
mortality, cardiovascular
exercise and, 79–80
smoking and, 41
weight loss and, 183–4
Multiple Risk Factor Intervention Trial, 135, 156
myocardial infarction (MI), 41–2, 137–9
myositis, 167
myristic acid, 63, 64f
myxedema, 161
nasal spray, 48
National Cholesterol Education Program (NCEP), 163f
National Death Index, 183
National Health and Nutrition Examination Survey (NHANES), 134
National Health Interview Survey, 183
neurological disorders, 98–101
dementia, 100–101
obesity and, 98–101
stroke, 98–100
nicotinamide adenine dinucleotide phosphate reduced form (NADPH), 43f
nicotine gum, 48
nicotine replacement therapy (NRT), 51
nicotine vaccines, 50
nicotine withdrawal symptoms, 47
nicotinic acid, 164f, 171–2
mechanisms of action, 171–2
side effects, 172
Niemann-Pick C1 Like 1 protein (NPC1L1), 170
nitric oxide, 43f
nitric oxide synthase, 43f
non-high density lipoprotein cholesterol, 31, 144–6, 145f, 146f
normal fasting glucose (NFG), 4f
normal glucose tolerance (NGT), 7f
normal weight, 97f
nortriptyline, 48
nutrition, 59–70
dietary carbohydrate, 67–8
dietary fat, 59–61
body weight and, 60
lipoprotein profiles, 60–61
polyunsaturated fatty acids, 63–6
saturated fatty acids, 63–4
types of, 61–7
dietary fat level, 59–61
dietary fat types, 61–7
dietary supplements, 69–70
Mediterranean diet, 60
plasma lipoproteins, 67
protein, 68–9

obesity, 96–111
age and, 100
assessment of adiposity, 108
body mass index, 96, 97
cardiovascular disease and, 98–108
congestive heart failure, 104–8
coronary artery disease, 101–4
central, 99
in children, 96, 97, 98
definition of, 97–8
diabetes mellitus and, 146–7
energy balance, 182
energy intake and expenditure, 181, 182
functional and structural changes, 108
management of, 108–10
mass effects, 182
neurological disorders and, 98–101
dementia, 100–101
stroke, 98–100
sarcopenic, 107
susceptibility genes, 98
trans fatty acids and, 228–9
waist circumference, 98, 106–7
waist circumference measurements, 98
waist-to-hip ratio (WHR), 98, 106–7
obesity management, 181–91
effect on mortality, 183–4
effects on morbidity, 184–92
diabetes, 187–92
dyslipidemia, 186–7
heart disease, 184–6
hypertension, 184–6
obstructive sleep apnea, 186
intermediate risk factors, 184
obesity paradox, 100, 105–8
obstructive sleep apnea (OSA), 124, 126
oleic acid, 63, 64
omega-3 fatty acids, 164, 174
omega-3 polyunsaturated fatty acids, 65–6
oral contraceptives, 42
oral glucose tolerance test (OGTT), 6, 8–9, 10f, 135
orlistat, 188, 189
overweight, 97
oxygen supply, and smoking, 44–5
palmitic acid, 63, 64
palmitoleic acid, 64
pellagra, 171
percutaneous transluminal coronary angioplasty (PTCA), 103
pericardial fat, 102
perindopril, 205–6
peroxinitrite, 43
peroxisome proliferator-activated receptor-α (PPAR-α), 173
physical activity, 77–90. See also lifestyle modifications
aerobic exercise, 88, 89
assessment, 88–90
cardiopulmonary fitness and, 87
cardiovascular disease and, 81
atherogenic dyslipidemia, 84–5
dose–response relations, 82
hypertension, 82–3
stroke, 82
cardiovascular morbidity and, 79–80
cardiovascular mortality and, 79–80
cardiovascular risk reduction, 221, 224–6
continuum of disease state, 79
continuum of exercise response, 79–80
continuum of exposure, 78–9
coronary heart disease and, 80–81
counseling, 88–90
dose response, 78–9
exercise volume, 78
guidelines for Americans, 88, 89
heart failure and, 88
limitations, 78
vascular health and, 85–7
arterial stiffness, 86–7
brachial artery flow-mediated dilatation, 85
carotid intimal-medial thickening, 85–6
Physical Activity Guidelines for Americans, 88
physical inactivity, 224–6
phytosterols, 69
Pima Indians, 6, 7f
plant sterols, 69
plasma lipoprotein, 67
plasminogen activator inhibitor (PAI), 101f
policosanols, 70
polycystic ovary syndrome, 121
polydipsia, 124
polyphagia, 124
polyunsaturated fatty acids, 63–6
polyuria, 124
postprandial lipemia, 160
postprandial lipoprotein, 21–2
pravastatin, 157–8, 165f
PROactive, 210–11
protein, 68–9. See also nutrition
soy, 68–9
types, 68
proteinuria, 142, 160
PUMA-G receptor, 171
reverse cholesterol transport, 34
rhabdomyolysis, 167–8, 174
rimonabant, 50
rosuvastatin, 159, 165f
Roux-en-Y gastric bypass, 127
RP-TFA (ruminant-produced trans fatty acids), 228–9
ruminant fat, 228–9
sarcopenic obesity, 107
saturated fatty acids, 63–4
Scandinavian Simvastatin Survival Study, 157
schizophrenia, 47
7-Day Physical Activity Recall, 88–90
short-chain fatty acids, 63
sibutramine, 189–91
simvastatin, 165f, 166, 168f, 170–71
sitosterol, 69
sleep, 227–8
sleep apnea, 186
smoking, 41–53, 223–4
adverse life events and, 47–8
age, 52
atherosclerosis and, 41–4
decreased oxygen supply, 44–5
endothelial injury or dysfunction, 42
fibrinolysis, 42
increased blood rheology, 44–5
inflammation, 44
lipids and lipid metabolism, 44
thrombosis, 42
cardiovascular deaths, 41
cardiovascular dysfunction, 43f
cardiovascular function and, 44
cessation
drugs, 48–50
effectiveness of, 48–52
inpatient programs, 51–2
weight gain and, 46
demographics, 52
ethnicity, 52
genetic factors, 48
gender, 52
giving up, 221
ischemic heart disease and, 41–2
metabolic syndrome and, 45–8
adverse life events, 47–8
depression, 46–7
geneic factors, 48
risk factors, 46
and risk for coronary heart disease, 163t
tobacco use, 52
withdrawal symptoms, 47
women smokers, 46
soy protein, 68–9
soybean oil, 65
Stanford Brief Physical Activity Score, 88–90
Stanford Coronary Risk Intervention Project, 185
statins, 127, 157, 164f
mechanisms of action, 165–6
side effects, 166–8
structure, 165f
stearic acid, 63, 64f
sterol receptor element binding protein 1-C (SREBP 1-C), 11, 174
stigmasterol, 69
stroke, 82, 98–100
subcutaneous fat, 12–13
substance P, 42
sucrose, 68
suicides, 50
superoxide, 43f
Swedish Obese Subjects study, 184
systolic blood pressure, 83, 149f
testosterone, 35
therapeutic lifestyle changes (TLC), 162, 220–29
alcohol consumption, 221–2
blood pressure, 222
diabetes control, 222
diet, 221, 227–9
medications, 222
physical activity, 221, 224–6
sleep, 227–8
smoking cessation, 221, 223–4
weight control, 221
thiazide diuretics, 162
thiazolidinediones, 7, 126
thrombosis, 42
tissue plasminogen activator (TPA), 42
tobacco use, 41–53
adverse life events and, 47–8
age, 52
atherosclerosis and, 41–4
decreased oxygen supply, 44–5
endothelial injury or dysfunction, 42
fibrinolysis, 42
increased blood rheology, 44–5
inflammation, 44
lipids and lipid metabolism, 44
thrombosis, 42
cardiovascular deaths, 41
cardiovascular dysfunction, 43f
cardiovascular function and, 44
cessation, 223–4
effectiveness of, 48–52
inpatient programs, 51–2
weight gain and, 46
ethnicity, 52
gender, 52
 genetic factors, 48
giving up, 221
ischemic heart disease and, 41–2
metabolic syndrome and, 45–8
adverse life events, 47–8
depression, 46–7
 genetic factors, 48
risk factors, 46
and risk for coronary heart disease, 163f
withdrawal symptoms, 47
total cholesterol (TC), 143–4f, 148–9f,
163f
smoking and, 44
trans fatty acids, 66–7, 227–9
industrially-produced, 228–9
metabolic syndrome and, 228–9
obesity and, 228–9
ruminant-produced, 228–9
Treating to New Targets (TNT) study, 158
Trial of Nonpharmacologic Interventions in the Elderly (TONE), 184
Trials of Hypertension Prevention (TOHP), 184
triglyceride-rich lipoproteins, 19, 20–22
atherogenicity, 27
defects in production of, 23
diabetes mellitus and, 143–4f
intestinal, 20–22, 20f
residual risk for CHD, 35
troglitazone, 7
tumor necrosis factor (TNF), 101f
type 1 diabetes mellitus
 insulin and, 2
mortality rate, 135
type 2 diabetes mellitus
 high-fructose diet and, 68
insulin deficiency in, 2, 9
insulin resistance in, 2
lifetime risk, 135
mortality rate, 135
underweight, 97f
United Kingdom Prospective Diabetes Study, 142, 199, 208–10
US Diabetes Prevention Program (UDPP), 187
VADT, 206–8
varenicline, 49–50
vascular health, 85–7
arterial stiffness, 86–7
brachial artery flow-mediated dilation, 85
carotid intimal-medial thickening, 85–6
vegetable protein, 68
very-low-density lipoprotein cholesterol (VLDL-C), 30–31
hypertriglyceridemia and, 60
smoking and, 44
very-low-density lipoproteins (VLDL), 19, 22–7
apoB lipoproteins, synthesis of, 22
apolipoprotein B lipoproteins, 22–3
clinical applications, 22
dyslipidemia, diagnosis of, 160
free fatty acids, increase in, 11
hypertriglyceridemia and, 25–7, 61
metabolism, 22, 24 f
metabolism in plasma, 23
statin therapy, 166
structure, 19 f

vitamin C, 70
vitamin E, 70
waist circumference, 98, 106–7
waist-to-hip ratio (WHR), 98, 106–7
weight control, 221
weight gain, 46, 68
weight loss, 183–92. See also lifestyle modifications; obesity management
benefits of, 110 t
effect on mortality, 183–4
effects on morbidity, 184–92
diabetes, 187–92
dyslipidemia, 186–7
heart disease, 184–6
hypertension, 184–6
obstructive sleep apnea, 186
intentional vs. unintentional, 183
intermediate risk factors, 184
West of Scotland Coronary Prevention Study, 157
women smokers, 46
Women’s Health Initiative, 60
xanthelasmas, 161